Drugs / Conventional T-Cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01660607 | Feb 2012 → Dec 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Stanford University | Completed | No outcome recorded |
| Phase 1/2 | NCT01050764 | Jun 2009 → Aug 2012 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Everett Meyer | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03977103 | Feb 2014 → Feb 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, plasma cell myeloma | University Of Perugia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conventional T-cells | “Patients received an infusion of 2 × 106/kg donor regulatory T cells on day -4 followed by 1 × 106/kg donor conventional T cells on day -1 and a mean of 10.7 × 106 ± 3.4 ×...” PMID 33646302 ↗ Mar 2021 |
| Known as | Tcon | “Conventional T-Cells (Tcon)” NCT01660607 ↗ |
| Modality | Cell therapy | “These are conventional (unselected) donor T-cells.” NCT01050764 ↗ |